Skip to Main Content

Paper Details

Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Clin Ther
8
2022
Author NameAffiliation
William J SandbornUniversity of California San Diego
  • 1 - 1

Datasets

Release 1.2